You are the leader of the connect the dot clan. While the speculation is interesting while we all wonder how this will unfold, it leads to expectations that are not based in fact.

I never locked into a large up-front payment for the inking of a LymPro partner. I think I even made a post back on IHUB that while some were expecting large up-front payment, that would also entail a higher percentage of revenues going to the partner, and GC might negotiate a lower payment and retain a higher percentage of revenues for Amarantus.

There was also discussions of the company bringing LymPro to market alone, i.e. no JV partner. So while you might not have been alone in expectations of a large up-front payment in a "classic" partnership, the reality is the company never stated this. Some just assumed that's the path they would take based on connecting the dots to support other speculations.

Now shareholders want to claim we were misled... by the management of a pre-revenue biotech where the regulatory and business environment is constantly shifting under their feet, and they feel management should have their feet held to the fire... and even a stellar management team like the one Amarantus has assembled should not be fully trusted. Give me a break.

Some investors should simply stick to mutual funds.